Current - 43 seconds ago
Grey lines are ignored Blue lines are triggers
|
* polaris innovation fund
* polaris growth fund
* limited partners
* Portfolio
* Team
* About
working alongside
entrepreneurs to foster
innovation and build
impactful companies
working alongside
entrepreneurs to foster
innovation and build
impactful companies
about the fund
The Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early-stage
academic research. By partnering with passionate entrepreneurs with transformational science, the
Polaris Innovation Fund fosters company creation and growth through an active investment model. Our team
brings decades of experience in healthcare investing and entrepreneurship to our guidance of early stage companies.
This team of proven leaders in scientific research, biopharma, and venture capital investment
joined together for the sole purpose of bringing biomedical innovation to the market.
the team
* Amy Schulman
Managing Partner
* Ellie McGuire
Managing Partner
* Robert Langer
Scientific Advisory Committee Member
* Daniel Anderson
Scientific Advisory Committee Member
* Terry McGuire
Founding Partner
* Alexandra Cantley
Partner
* Sharif Vakili
Entrepreneur Advisor
* Nil Gural
Senior Associate
* Manik Kuchroo
Senior Associate
portfolio
Amunix Pharmaceuticals
Mountain View, CA
Acquired by Sanofi
Amunix is a platform company developing technology for tumor-specific activation of T-cell engagers.
Ankyra
Boston, MA
Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer.
Howard L. Kaufman, MD, FACS
President & CEO
BeMe Health
BeMe Health is a digital mental health company focused on the support and treatment of teens and adolescents struggling with mental illness.
www.bemehealth.com
@bemehealthcare
Nicoletta Tessler
CEO
ByHeart
New York, NY
ByHeart is a fully integrated infant nutrition company dedicated to translating leading nutrition science and breastmilk research into products that set the best foundation for babies’ health.
Ron Belldegrun
CEO & Co-Founder
Mia Funt
President & Co-Founder
Candesant Biomedical
San Francisco, CA
Candesant is dedicated to developing novel solutions for excessive sweating and hyperhidrosis
Niquette Hunt
CEO
Delphia Therapeutics
Cambridge, MA
Delphia is pioneering activation lethality – a next-generation precision medicine approach targeting cancer’s vulnerability to oncogene overactivation.
www.delphiatx.com
Kevin Marks, PhD
President & CEO
Dewpoint Therapeutics
Cambridge, MA
Dewpoint is translating new insights into biomolecular condensates and cellular function to uncover treatments for the toughest disease.
www.dewpointtherapeutics.com
Ameet Nathwani
CEO
Engine Biosciences
Singapore
Engine Biosciences is a Singapore-based drug discovery company using a proprietary AI and CRISPR-based platform to identify novel precision oncology targets.
Jeffrey Lu
Co-Founder & CEO
Folx Health
Boston, MA
Folx Health is a digital health and wellness platform that delivers personalized, consumer grade, Queer-competent health care, centered on the LGBTQIA community.
@folxhealth
Liana Douillet Guzmán
CEO
Glympse Bio
Cambridge, MA
Glympse Bio is transforming disease monitoring with a novel class of highly tunable and bioengineered activity sensors that query the body for disease status and report out clinically relevant insights rapidly and noninvasively.
www.glympsebio.com
@GlympseBio
Caroline J. Loew
President & CEO
Hummingbird Bioscience
Singapore
Hummingbird focuses on engineering and developing next-generation therapies against important biologically validated targets in cancer and autoimmune disease which have been elusive and difficult to drug.
@hummingbirdbio
Piers Ingram
CEO, Co-Founder, Executive Director
IconOvir
San Diego, CA
IconOvir engages in research and development in cancer viral gene therapy.
www.iconovir.com
Mark McCamish, M.D., Ph. D.
President & CEO
Kallyope
New York, NY
Kallyope is developing an industry-leading platform to harness the gut-brain axis.
www.kallyope.com
Jay Galeota
CEO
KenSci
Seattle, WA
KenSci is a healthcare data science company that uses machine learning to provide operational and clinical insights for hospital and health systems.
www.kensci.com
@KenSci
Sudarshan Chitre
CEO
Kronos Bio
San Mateo, CA
NASDAQ: KRON
Kronos Bio is dedicated to the discovery and development of novel small molecule modulators of historically undruggable oncology targets.
@KronosBio
Norbert Bischofberger
CEO
Montis Biosciences
Belgium
Montis Biosciences is targeting perivascular macrophages to restore tumor micro environment vasculature- increase immune infiltration and alleviate the immune suppressive TME.
www.montisbiosciences.com
Luc Dochez
Executive Chairman
Muna Therapeutics ApS
Copenhagen, Denmark
Muna Therapeutics is a neurology focused biotech company working on developing novel therapeutics for neurodegenerative diseases.
Rita Balice-Gordon
CEO
Nomad Health
New York, NY
Nomad Health is a workforce marketplace that facilitates the hiring of physicians and nurses on behalf of healthcare provider organizations.
www.nomadhealth.com
@nomad_health
Alex Nazem
CEO
One Health Company
Palo Alto, CA
The One Health Company, maker of FidoCure®, is bringing the latest advances in human oncology – individualized, precision medicine – to dogs with cancer.
@FidoCure
Christina Lopes
Founder & CEO
QurAlis
Cambridge, MA
QurAlis is developing precision therapies for the treatment of ALS.
www.quralis.com
@QurAlisCo
Dr. Kasper Roet
Founder & CEO
Satellite Bio
Cambridge, MA
Satellite Bio has pioneered a novel type of regenerative medicine, Adaptive Tissue Therapeutics, to target a range of elusive, life-threatening diseases.
Laura Lande-Diner
CBO & President
Thomas Lowery
CTO & President
Sesh Therapy
San Francisco, CA
Sesh Therapy offers online support group sessions facilitated by a trained therapist.
www.seshtherapy.com
Vittoria Bergeron
CEO & Co-Founder
SunBird Bio
Cambridge, MA / Singapore
SunBird Bio is developing protein-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of Alzheimer’s disease, other neurological disorders and early-stage cancer. Through its merger with Glympse Bio, SunBird Bio brings two leaders in the protein diagnostics field together to focus on platform development and improve patients outcomes.
John McDonough
Executive Chairman & CEO
Suono Bio
Cambridge, MA
Suono Bio, Inc. enables ultrasonic targeted delivery of therapeutics and macromolecules across tissues without the need for reformulation or encapsulation. Preclinical studies have demonstrated the capacity to deliver small molecules, proteins, vaccines, and nucleic acids locally to specific tissues such as the gastrointestinal tract, as well as systemically in a formulation-independent manner.
www.suonobio.com
@suonobio
Scott Kellogg
CEO
Thirty Madison
New York, NY
Thirty Madison is an end-to-end digital health platform that connects patients directly to provider specialists.
@thirtymadison
Steven Gutentag
CEO & Co-Founder
Vico Therapeutics
The Netherlands
Vico Therapeutics is developing therapies for rare neurological diseases, leveraging RNA modifying technologies.
Micah Mackison
CEO
Volastra
New York, NY
Volastra is developing novel therapeutics to tackle hard to treat cancers by harnessing unique insights into the mechanisms by which Chromosomal Instability impact and drive cancer cells.
Charles Hugh-Jones
CEO
Oui Health
New Haven, CT
Oui is developing an app to help manage mental health.
Seth Feuerstein
CEO
Capstan Therapeutics
Philadelphia, PA
Capstan Therapeutics is developing a targeted delivery platform and therapeutics to reprogram immune cells in vivo for a broad range of disease categories.
@capstantx
Laura Shawver
President & CEO
EpiBiologics
San Mateo, CA
EpiBiologics is a next generation targeted protein degradation company developing antibody-based therapeutics that degrade extracellular or transmembrane targets.
Ann Lee-Karlon, Ph.D.
CEO and President
65LAB
Singapore
65LAB serves as a biotech company incubator which identifies, funds and supports the formation of new companies sourced from academic and research institutions in Singapore.
Larkspur Biosciences
Watertown, MA
Larkspur Biosciences is developing precision immunotherapies targeting the key intersection between the tumor and the immune system.
www.larkspur.bio
Catherine Sabatos-Peyton, PhD
CEO
Triveni Bio
Waltham, MA
Triveni Bio is a biotechnology company focused on providing a genetics-informed precision medicine approach for I&I disorders. The company is the result of a merger between Amagma Therapeutics, a Polaris portfolio company, and Modify Therapeutics.
Vishal Patel, PhD
CEO
UpDoc
Palo Alto, CA
UpDoc is a tech-enabled services company providing the first-ever proprietary conversational AI platform for medication management.
Sharif Vakili
CEO & Co-Founder
Full Company list
contact
Polaris Innovation Fund
One Marina Park Drive, 8th Floor
Boston, MA 02210
855.787.3500
General inquiries: partnership@polarispartners.com
* Boston
* New York
* San Francisco
* Email Us
* LinkedIn
* Terms of Use & Privacy Policy
* Important Disclosures
|
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires Playwright/WebDriver enabled